According to earlier studies, mutations in the Akt2 isoform are quite rare whilst amplifications in the isoform have been detected in 16% of pancreatic cancers; 16% of uterine cancers; 13% of breast cancers; and 5–10% of ovarian, lung, and bladder cancers. This evidence concerns the gene AKT2 and breast carcinoma.